VA-HEMOSONICS
10.9.2019 22:37:09 CEST | Business Wire | Press release
HemoSonics is excited to announce that its new QStat Cartridge, an extension of its groundbreaking Quantra Hemostasis System, has registered for CE Mark and is now commercially available in Europe and Hong Kong. The utility of the Quantra System, which was previously available with the QPlus Cartridge for cardiovascular and major orthopedic surgeries, is now expanded with the addition of the QStat Cartridge and can now be used across the hospital in trauma surgery and liver transplant settings. The Quantra System provides rapid, actionable coagulation results at the point of care, giving clinicians the opportunity to make informed bleeding management decisions when time is critical.
Improving patient outcomes and facilitating goal-directed therapy is the primary focus of any diagnostic system. But the new Quantra System is breaking new ground in point-of-care viscoelastic testing (VET) efficiency by combining rapid time to results, clear outputs, and a simple intuitive design. SEER (Sonic Estimation of Elasticity via Resonance) Sonorheometry, the revolutionary ultrasound technology, is the foundation of this remarkably efficient and reliable analyzer, which now offers an expanded menu of whole-blood tests in two self-contained cartridges; QPlus® for cardiac and major orthopedic surgery, and QStat for trauma and liver transplant surgery.
The QStat Cartridge is a fully sealed, room-temperature stable, disposable cartridge that offers a panel of viscoelastic coagulation tests, including Clot Time (CT), Clot Stiffness (CS), Fibrinogen Contribution to Clot Stiffness (FCS), Platelet Contribution to Clot Stiffness (PCS), and Clot Stability to Lysis (CSL). All tests except the latter take 25 minutes or less to produce valid results (typically 12-15 minutes), whereas the clot lysis test (CSL) is enabled to run for up to 60 minutes. The Quantra System requires less than 60 seconds of operator’s hands-on time – and requires no pipetting or wait time after draw. Results are provided on an easy-to-read, user-friendly “dials” interface that does not require extensive training.
Studies have demonstrated strong correlation between the Quantra System and both standard laboratory tests and other viscoelastic hemostasis assays. In addition, the QStat Cartridge provides novel parameters designed specifically to give clear actionable information in critical care settings. The Quantra System reports both fibrinogen (FCS) and platelet contributions (PCS) to clot stiffness, giving clinicians the opportunity to quickly consider the most appropriate therapies to apply when bleeding is a concern. The Clot Stability to Lysis (CSL) test provides an adaptive and confirmatory result based on the level and onset time of clot lysis. Additionally, the Quantra QStat System directly analyzes and compares changes in clot stiffness in both the presence and absence of tranexamic acid, thus automatically correcting for potentially confounding results inherent to earlier VET systems.
“Trauma and liver surgeries pose an enormous risk of acute bleeding,” said Timothy J. Fischer , President and Chief Executive Officer of HemoSonics. “The Quantra QStat System is a breakthrough in point-of-care bleeding management because it provides rapid, reliable, and novel information to aid clinicians in their decision making in the ER, trauma bay, or post-operative ICU. What makes the new QStat Cartridge unique is its unparalleled ease of use and its innovative coagulation tests for critical injury and liver transplant, including Platelet Contribution to Clot Stiffness and Clot Stability to Lysis.”
Availability
The Quantra Hemostasis System, including QPlus and QStat Cartridges and 2 levels of external quality controls, is commercially available in countries within Europe.
In the United States, the Quantra Hemostasis Analyzer, QPlus Cartridge and associated external quality controls comprise the Quantra® QPlus® System which received de novo marketing authorization by the FDA in March of 2019. In the United States the QStat Cartridge is available for investigational use only.
About HemoSonics
HemoSonics is a medical device company with the primary mission to deliver clinical tools that provide actionable information in the critical care settings; resulting in better care for patients and lower overall medical costs.
The Quantra Hemostasis Analyzer, the flagship product of HemoSonics, is designed to improve patient outcomes and reduce healthcare costs by providing unique and optimized coagulation information, for easy and fast interpretation and simple, more efficient point-of-care bleeding management workflows.
HemoSonics is headquartered in Charlottesville, VA, with research, development and manufacturing facilities in Durham, NC. For more information, visit www.hemosonics.com .
HemoSonics is part of the Stago group, a leading company in the in vitro Diagnostics industry dedicated to the exploration of thrombosis and hemostasis.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910006110/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2027 Cocktail Trends Put a Fresh Spin on Classics, Flavor and the Night Out16.11.2026 13:00:00 CET | Press release
The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience The five emerging movements poised to shape cocktail culture in 2027 were unveiled today in the eighth annual Bacardi Cocktail Trends Report published by Bacardi Limited, the world’s largest privately held international spirits company. Created in collaboration with strategic foresight consultancy The Future Laboratory (TFL), the report combines global consumer research, bartender insights, and industry perspectives to explore how the cocktail experience is evolving. The report also reveals the top cocktails Legal Drinking Age (LDA) consumers plan to order at bars and venues worldwide throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116061749/en/ The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience in 2027. “F
Cordica Medical Launches PTFE Etched Liners for Interventional Catheter Designs16.11.2026 13:00:00 CET | Press release
32 webstore sizes ship in 48 hours, with custom sizes from 0.010" to 0.400" ID built in 2–3 weeks Cordica Medical (Cordica), a medical device contract development and manufacturing organization (CDMO), today launched its PTFE Etched Liner portfolio: lubricious ID, bond-ready etched OD PTFE liners for interventional catheter designs, from cardiovascular to neurovascular and more. Standard sizes are available now on the Cordica webstore and ship in 48 hours. Custom sizes are built in 2–3 weeks. The launch coincides with the first day of COMPAMED 2026 in Düsseldorf, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116876181/en/ Pictured: Cordica’s PTFE Etched Liner. Each liner has a low-friction PTFE inner diameter designed to facilitate device and guidewire passage with a chemically etched outer diameter surface that is designed to enhance bonding to the catheter jacket. The liners are designed to be drawn down over
Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 10:00:00 CET | Press release
Plural’s largest raise to date: almost four times its €260m inaugural fund in 2022, and double its €500m second fund in 2024 All former founders and operators, Plural’s partners back founders early to build generational companies that compete globally from Europe Plural’s companies have raised over €3bn in follow-on capital in the last twelve months alone as European tech accelerates Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe
SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools16.11.2026 09:36:00 CET | Press release
Initiative in Malawi, Burundi, Zambia and Zimbabwe will leverage SES satellite solutions to extend digital learning opportunities to 20,000-30,000 students and teachers. SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000 students and teachers in underserved and remote communities. Through SES’s solutions, the coalition has given students and educators access to online learning platforms, teacher-training resources and collaboration tools. These resources help schools strengthen digital skills and expand learning opportunities to allow students better participate in the futu
Regnology and ActiveViam Partner to Bring the Same Granular, Explainable Risk Intelligence to Banks and Their Supervisors16.11.2026 09:00:00 CET | Press release
ActiveViam’s Atoti analytics will extend from Regnology Risk Hub to Regnology Supervisory Hub, so the regulated and their regulators can ask their own questions of granular data Regnology, a leading global technology provider at the intersection of regulatory reporting, risk management, finance, and supervisory technology, today announced a strategic partnership with ActiveViam, the provider of Atoti, the AI-native enterprise risk intelligence platform for capital markets. The partnership embeds Atoti as the real-time risk aggregation and analytics engine in Regnology Risk Hub, and will extend it to supervisory authorities through Regnology Supervisory Hub. Regnology is the only provider whose offering serves both the regulated and their regulators, with more than 15,000 financial institutions and more than 100 authorities as clients. Markets and depositors now move within days, and the questions that follow rarely fit a predefined report. During the 2023 market turmoil, supervisors fa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
